178 related articles for article (PubMed ID: 11005773)
1. Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs.
van Dieten HE; Korthals-de Bos IB; van Tulder MW; Lems WF; Dijkmans BA; Boers M
Ann Rheum Dis; 2000 Oct; 59(10):753-9. PubMed ID: 11005773
[TBL] [Abstract][Full Text] [Related]
2. [Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases].
Soto Alvarez J
An Med Interna; 2000 Sep; 17(9):477-84. PubMed ID: 11100534
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
4. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
Al MJ; Maniadakis N; Grijseels EW; Janssen M
Value Health; 2008; 11(4):589-99. PubMed ID: 18194404
[TBL] [Abstract][Full Text] [Related]
5. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.
Al MJ; Michel BC; Rutten FF
Pharmacoeconomics; 1996 Aug; 10(2):141-51. PubMed ID: 10163417
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs.
Maetzel A; Ferraz MB; Bombardier C
Arthritis Rheum; 1998 Jan; 41(1):16-25. PubMed ID: 9433865
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis.
Kristiansen IS; Kvien TK; Nord E
Arthritis Rheum; 1999 Nov; 42(11):2293-302. PubMed ID: 10555023
[TBL] [Abstract][Full Text] [Related]
8. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations.
Stucki G; Johannesson M; Liang MH
Arch Intern Med; 1994 Sep; 154(18):2020-5. PubMed ID: 8092907
[TBL] [Abstract][Full Text] [Related]
9. Diclofenac/misoprostol. Pharmacoeconomic implications of therapy.
Plosker GL; Lamb HM
Pharmacoeconomics; 1999 Jul; 16(1):85-98. PubMed ID: 10539124
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions.
Geis GS; Stead H; Wallemark CB; Nicholson PA
J Rheumatol Suppl; 1991 Mar; 28():11-4. PubMed ID: 1903808
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
[TBL] [Abstract][Full Text] [Related]
12. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol.
Goldstein JL; Larson LR; Yamashita BD
Am J Manag Care; 1998 May; 4(5):687-97. PubMed ID: 10179922
[TBL] [Abstract][Full Text] [Related]
13. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada.
Zabinski RA; Burke TA; Johnson J; Lavoie F; Fitzsimon C; Tretiak R; Chancellor JV
Pharmacoeconomics; 2001; 19 Suppl 1():49-58. PubMed ID: 11280105
[TBL] [Abstract][Full Text] [Related]
14. Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions.
Davis R; Yarker YE; Goa KL
Drugs Aging; 1995 Nov; 7(5):372-93. PubMed ID: 8573992
[TBL] [Abstract][Full Text] [Related]
15. [Is misoprostol effective in NSAID-induced gastrointestinal complications?].
Stucki G; Sangha O; Michel BA
Schweiz Med Wochenschr; 1996 Sep; 126(37):1573-8. PubMed ID: 8927962
[TBL] [Abstract][Full Text] [Related]
16. Does famotidine have similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy?
Wu CS; Wang SH; Chen PC; Wu VC
Int J Clin Pract; 1998 Oct; 52(7):472-4. PubMed ID: 10622088
[TBL] [Abstract][Full Text] [Related]
17. Use of misoprostol in the elderly: is the expense justified?
Stucki G; Johannesson M; Liang MH
Drugs Aging; 1996 Feb; 8(2):84-8. PubMed ID: 8845589
[TBL] [Abstract][Full Text] [Related]
18. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville.
Knill-Jones RP
Scand J Rheumatol Suppl; 1992; 96():59-62. PubMed ID: 1439626
[TBL] [Abstract][Full Text] [Related]
19. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding.
Edelson JT; Tosteson AN; Sax P
JAMA; 1990 Jul; 264(1):41-7. PubMed ID: 2113103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
